CT severity score: an imaging biomarker to estimate the severity of COVID-19 pneumonia in vaccinated and non-vaccinated population

Background In India, two vaccines received emergent use authorization, namely Covishield (a brand of the Oxford-Astra Zeneca vaccine manufactured by the Serum institute of India) and Covaxin (developed by Bharat Biotech) against COVID-19 disease. Chest CT is an objective way to assess the extent of...

Full description

Saved in:

Bibliographic Details
Published in:	Egyptian journal of radiology and nuclear medicine Vol. 53; no. 1; pp. 1 - 8
Main Authors:	Gurumurthy, Balasubramanian, Das, Sudha Kiran, Shetty, Sachin, Veerabhadrappa, Rakesh Chowkalli, Kosinepalli, Sai Siddartha, Dharamaraju, Swathi Hassan
Format:	Journal Article
Language:	English
Published:	Cairo Springer 12-04-2022 Springer Nature B.V Springer Berlin Heidelberg SpringerOpen
Subjects:	Age Bacterial pneumonia Cardiovascular disease Chronic obstructive pulmonary disease Coronaviruses Covaxin COVID-19 COVID-19 vaccines Covishield CT imaging CT severity score Diabetes Dyspnea Health aspects Hemoptysis Hypertension Immunization Infections Medical research Medicine, Experimental Pandemics Pneumonia Risk factors Severe acute respiratory syndrome coronavirus 2 Statistical analysis Vaccination United Kingdom India
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background In India, two vaccines received emergent use authorization, namely Covishield (a brand of the Oxford-Astra Zeneca vaccine manufactured by the Serum institute of India) and Covaxin (developed by Bharat Biotech) against COVID-19 disease. Chest CT is an objective way to assess the extent of pulmonary parenchymal involvement. This study aims to estimate the disease severity and outcome due to COVID-19 among vaccinated and non-vaccinated symptomatic patients and compare the same in Covishield versus Covaxin recipients using CT severity score. Results A total of 306 patients were retrospectively evaluated. The mean age was 62.56 ± 8.9 years, and males [n-208 (67.97%)] were commonly affected. Of 306 patients, 143 were non-vaccinated (47%), 124 were partially vaccinated (40%), and 39 were completely vaccinated (13%). CT severity scores were reduced in both Covishield and Covaxin recipients in comparison with the non-vaccinated group [[chi].sup.2 (2) = 16.32, p < 0.001]. There is a reduction in LOS among the vaccinated group, predominantly among the Covishield recipients. Conclusion Vaccination confers protection from severe SARS-CoV2 infection and is associated with an overall reduction in mortality.
ISSN:	0378-603X 2090-4762
DOI:	10.1186/s43055-022-00768-2